Mechanism of Action of a New Anti-CD38 Antibody: Enhancing Myeloma Immunotherapy | Semantic Scholar
ePosters - Inecalcitol Stimulates CD38 Expression in Multiple Myeloma and Acute Myeloid Leukemia Cell Lines
In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma | Journal of Hematology & Oncology | Full Text
![Annotating CD38 Expression in Multiple Myeloma with [18F]F–Nb1053 | Molecular Pharmaceutics](https://pubs.acs.org/cms/10.1021/acs.molpharmaceut.1c00733/asset/images/acs.molpharmaceut.1c00733.social.jpeg_v03 "Annotating CD38 Expression in Multiple Myeloma with [18F]F–Nb1053 | Molecular Pharmaceutics")
Annotating CD38 Expression in Multiple Myeloma with [18F]F–Nb1053 | Molecular Pharmaceutics
Immunophenotyping in Multiple Myeloma and Others Monoclonal Gammopathies | IntechOpen
CD38 - Wikipedia
Frontiers | CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide
KoreaMed Synapse
Cells | Free Full-Text | CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents
Double CD38−/CD138− negative multiple myeloma - ScienceDirect
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab | Leukemia
Cells | Free Full-Text | Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model
Detect CD38 expression during anti-CD38 therapy – Caltag Medsystems
CD38, A Target for Immunotherapeutic Approaches in Cancer
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formatio
Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients | Haematologica
Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients | Haematologica
A Guide to Plasma Cell Markers | Biocompare: The Buyer's Guide for Life Scientists
Cureus | Secondary Plasma Cell Leukemia in a Recurrent Multiple Myeloma: Rare Case Scenario | Article
High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action - Adams - 2019 - Cytometry Part A - Wiley Online Library
Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies
International Clinical Cytometry Society
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma - ScienceDirect
